Armbruster Capital Management’s Novartis NVS Stock Holding History

Armbruster Capital Management’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-446	Closed	-$33K	–	283
2016 Q2	$33K	Hold	446	–	–	0.02%	150
2016 Q1	$29K	Sell	446 -134	-23%	-$9.12K	0.02%	165
2015 Q4	$45K	Buy	+580	New	+$46.1K	0.04%	140

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return

Armbruster Capital Management's NVS Position: Q3 2016 in Review

Armbruster Capital Management sold out of Novartis (NVS) in Q3 2016, closing a stake of 446 shares — an estimated $33K sold.

Armbruster Capital Management first reported a position in NVS in Q4 2015 and held it in 3 quarters. The position peaked at $45K in Q4 2015. 877 funds tracked by Wall St. Rank hold NVS as of Q3 2016.

Armbruster Capital Management reported no remaining Novartis position as of Q3 2016 after selling out during the quarter.
Armbruster Capital Management sold 446 Novartis shares in Q3 2016, an estimated $33K.
Armbruster Capital Management first reported a position in Novartis in Q4 2015 and held it in 3 quarters.
Armbruster Capital Management's Novartis position peaked at $45K in Q4 2015.
877 funds tracked by Wall St. Rank held Novartis as of Q3 2016.

Based on Armbruster Capital Management's 13F filing for Q3 2016, filed 25 Oct 2016.